Repository logo
 

An integrated computational approach can classify VHL missense mutations according to risk of clear cell renal carcinoma.


Change log

Authors

Gossage, Lucy 
Pires, Douglas EV 
Olivera-Nappa, Álvaro 
Asenjo, Juan 
Bycroft, Mark 

Abstract

Mutations in the von Hippel-Lindau (VHL) gene are pathogenic in VHL disease, congenital polycythaemia and clear cell renal carcinoma (ccRCC). pVHL forms a ternary complex with elongin C and elongin B, critical for pVHL stability and function, which interacts with Cullin-2 and RING-box protein 1 to target hypoxia-inducible factor for polyubiquitination and proteasomal degradation. We describe a comprehensive database of missense VHL mutations linked to experimental and clinical data. We use predictions from in silico tools to link the functional effects of missense VHL mutations to phenotype. The risk of ccRCC in VHL disease is linked to the degree of destabilization resulting from missense mutations. An optimized binary classification system (symphony), which integrates predictions from five in silico methods, can predict the risk of ccRCC associated with VHL missense mutations with high sensitivity and specificity. We use symphony to generate predictions for risk of ccRCC for all possible VHL missense mutations and present these predictions, in association with clinical and experimental data, in a publically available, searchable web server.

Description

Keywords

Carcinoma, Renal Cell, Computational Biology, Computer Simulation, Genetic Predisposition to Disease, Humans, Kidney Neoplasms, Mutation, Missense, Phenotype, Von Hippel-Lindau Tumor Suppressor Protein, von Hippel-Lindau Disease

Journal Title

Hum Mol Genet

Conference Name

Journal ISSN

0964-6906
1460-2083

Volume Title

Publisher

Oxford University Press (OUP)

Rights

DSpace@Cambride licence
Sponsorship
Cancer Research Uk (None)
This work was supported by a Cancer Research UK Hales fellowship (Dr Lucy Gossage), the  Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (Dr Douglas Pires),  the Institute for Cell Dynamics and Biotechnology (ICM project # P05‐001‐F) and the Centre  for Biotechnology and Bioengineering, University of Chile (CeBiB, project FB0001) and  Fondecyt Project No. 1141311.